DUBLIN–(BUSINESS WIRE)–The “Global
Anti-obesity Drugs Market 2018-2022” report has been added to ResearchAndMarkets.com’s
offering.
The anti-obesity drugs market is projected to register a CAGR of almost
8% by 2023.
The research on drugs that target obesity and type 2 diabetes mellitus
to gain traction in the market. The global epidemic of obesity and type
2 diabetes is increasing. This demands increasing focus on the drugs
that can control obesity and diabetes.
Global increase in both incidence and prevalence of obesity
The prevalence and incidence rate of obesity is very high because of the
limited efficacy of currently available drugs. The prevalence of obesity
remains the highest in the US over the past two decades. Thus, the shoot
in the rates of obesity across the world offers huge opportunities for
drug manufacturing vendors to manufacture innovative and highly
effective drugs.
Limited reimbursement for anti-obesity drugs
Although US is the major market for anti-obesity drugs, the challenges
associated with the reimbursement of these drugs is more in the US.
Bariatric surgery can recover weight related issues and is life-saving,
but the concern for financial burden remains. People are unwilling to
pay for this surgery as they believe that obesity is a cosmetic or
lifestyle issue, which led player limit coverage.
Market Trends
- Research on Drugs that Target Both Obesity and Type 2 Diabetes Mellitus
- Increase in Childhood Obesity Incidence
- Use of Implantable Neuroregulatory Devices for Treating Obesity
- Increase in Morbid Obesity Incidence
Key Players
- Eisai
- Novo Nordisk
- Vivus
Topics Covered
1. Executive Summary
2. Scope of the Report
3. Research Methodology
4. Market Landscape
5. Market Sizing
6. Five Forces Analysis
7. Pipeline Analysis
8. Market Segmentation by Drugs Based on Class of Obesity
9. Market Segmentation by Mechanism of Action
10. Customer Landscape
11. Regional Landscape
12. Decision Framework
13. Drivers and Challenges
14. Market Trends
15. Vendor Landscape
16. Vendor Analysis
For more information about this report visit https://www.researchandmarkets.com/research/k3n82x/worldwide?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Anti-Obesity
Drugs
